Norgine Gains CHMP Nod for Mavorixafor in Treating Rare WHIM Syndrome
- Norgine B.V. receives a positive CHMP recommendation for marketing authorization of XOLREMDI® to treat WHIM syndrome.
- Norgine partners with X4 Pharmaceuticals to commercialize mavorixafor in Europe, Australia, and New Zealand post-approval.
- CEO Janneke van der Kamp highlights Norgine's commitment to innovative therapies for patients with rare diseases.
Norgine Advances Treatment Options for Rare Disease with Positive Regulatory Recommendation
Norgine B.V. secures a critical regulatory milestone with a favorable opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding its drug XOLREMDI® (mavorixafor). This recommendation aims to provide a marketing authorization for treating WHIM syndrome in patients aged 12 and older. WHIM syndrome, an ultra-rare disorder marked by warts, infections, hypogammaglobulinemia, and myelokathexis, results from a dysfunction of the CXCR4 chemokine receptor. This dysfunctional receptor severely hampers white blood cell mobilization from the bone marrow, leading to recurrent and life-threatening infections. The absence of licensed treatments for this condition underscores the significance of this development, which addresses an essential medical need within the rare disease community.
The CHMP’s positive opinion stems from a pivotal phase 3 clinical trial, dubbed 4WHIM, which involved 31 patients diagnosed with WHIM syndrome. The global, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of mavorixafor. By demonstrating favorable results during trials, Norgine positions mavorixafor as a potential breakthrough therapy for individuals grappling with this debilitating condition. With the European Commission's final decision on the authorization expected in the second quarter of 2026, Norgine moves forward, anchoring its commitment to innovate treatment options for patients facing daunting health challenges.
In January 2025, Norgine entered into a strategic licensing and supply agreement with X4 Pharmaceuticals, granting the company rights to commercialize mavorixafor across Europe, Australia, and New Zealand post-regulatory approval. Under this agreement, Norgine will spearhead market access and commercialization efforts, while X4 is responsible for manufacturing and supplying the drug. Janneke van der Kamp, CEO of Norgine, articulates the company’s dedication to delivering transformative therapies to underserved patient populations, affirming that this recent recommendation marks a pivotal step in catering to the complex medical needs associated with rare diseases like WHIM syndrome.
In parallel developments, the pharmaceutical landscape sees other companies making significant strides. For instance, Eli Lilly announces a positive opinion from the EMA regarding Olumiant (baricitinib) as a treatment for severe alopecia areata in adolescents, backed by robust phase 3 study data. Such advancements catch the public eye and exemplify the ongoing efforts within the industry to address unmet medical needs across various demographics. As Norgine continues on its current trajectory, the collaboration with X4 Pharmaceuticals positions the company strongly within the specialty pharmaceutical sector, aiming to make a notable impact for patients dealing with rare and complex health conditions.